Meeting
2017 ASCO Annual Meeting
Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Authors
Michael J. Morris
Memorial Sloan Kettering Cancer Center and Weil Cornell Medical College, New York, NY
Michael J. Morris , Nicholas J. Vogelzang , Oliver Sartor , Alison Armour , Michael Groaning , Adam Robarts , Daniel Peter Petrylak , Anthony W. Tolcher , Michael S. Gordon , Hani M. Babiker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02202447
Citation
J Clin Oncol 35, 2017 (suppl; abstr 5038)
DOI
10.1200/JCO.2017.35.15_suppl.5038
Abstract #
5038
Poster Bd #
112
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
PRIMERA trial (NCT04188275), early survival results from a prospective trial exploring impact of circulating tumor cell detection in castrate resistant prostate cancer patients undergoing abiraterone or enzalutamide I line treatment.
First Author: Giulio Francolini
Poster
2018 ASCO Annual Meeting
A phase I study of 177Lu-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).
First Author: Megan Crumbaker
Poster
2016 ASCO Annual Meeting
Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Michael J. Morris
Poster
2023 ASCO Annual Meeting
The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.
First Author: Siyuan S Guo